Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481381 | 1.00 | PPARG (0.39) | PPARGPTPN1PPARAPPARDKDM4E | |
| SCHEMBL4479563 | 0.88 | PTPN1 (0.41) | PPARGPTPN1 | |
| SCHEMBL4479567 | 0.88 | PTPN1 (0.41) | PPARGPTPN1 | |
| SCHEMBL4477988 | 0.84 | PTPN1 (0.40) | PPARGPTPN1PPARA | |
| SCHEMBL4477990 | 0.84 | PTPN1 (0.40) | PPARGPTPN1PPARA | |
| SCHEMBL4491657 | 0.80 | — | — | |
| SCHEMBL4491659 | 0.80 | — | — | |
| SCHEMBL3292591 | 0.80 | PTPN1 (0.38) | PPARGPTPN1PPARA | |
| SCHEMBL3292593 | 0.80 | PTPN1 (0.38) | PPARGPTPN1PPARA | |
| SCHEMBL4471599 | 0.79 | PPARG (0.39) | PPARGPTPN1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557123-B2 | Heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1403253-A1 | NOVEL HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220215-A1 | Novel heterocyclic compound and medicinal use thereof | GPR119, INSR, GLP1R | PPARG 6/4885PTPN1 750/4885PPARA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.